Vimta Labs gets nod for foray into biologics CDMO business

29 Apr 2025 Evaluate

Vimta Labs has received approval for foray into biologics contract research and development activities (CDMO). The estimated amount to be invested is Rs 50 crore. The foray into this new segment will help the company to enter into the growing CDMO business of biologics and peptides, that will strengthen its service portfolio to biopharmaceutical industry, enabling acceleration of its business growth. The board of directors of the company in its meeting held on April 28, 2025, has approved the same.

Vimta Labs is India’s leading contract research and testing organization.

Vimta Labs Share Price

611.10 -8.80 (-1.42%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 654.25
Indegene 520.25
CMS Info Systems 344.60
Sagility 52.62
Smartworks Coworking 468.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×